Biological Anti-aging Efficacy of a Cosmetic Night Cream
NCT ID: NCT06433323
Last Updated: 2024-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
46 participants
OBSERVATIONAL
2024-05-23
2024-07-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
46 subjects are included
4 visits are planned:
* Visit 1 (D1): Inclusion and 1st product application
* Visit 2 (D28): Phone call follow-up
* Visit 3 (D57): End of application and biopsies
* Visit 4 (7 days after V3): Biopsies control and end-of-study
For a subject completing the study, the theoretical investigational product application will be 56 consecutive days up to 59 days maximum.
The maximal duration of participation for a subject is 68 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treated group : Healthy female adults
Anti-aging cosmetic care product
This is an intra-individual comparison study.
* frequency of application: Once a day (in the evening)
* modalities of application: Apply the cream on the tested area determined by the randomization
* duration of investigational product application: 56 days (a window of + 72 hours is allowed)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-aging cosmetic care product
This is an intra-individual comparison study.
* frequency of application: Once a day (in the evening)
* modalities of application: Apply the cream on the tested area determined by the randomization
* duration of investigational product application: 56 days (a window of + 72 hours is allowed)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Criteria related to the subject's health / skin :
* Subject having any dermatologic condition or characteristics (like tattoo) on any of the target areas liable to interfere with the study assessments
* Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
* Subject having received on any of target areas artificial UV exposure, excessive or prolonged exposure to natural sunlight within 2 weeks before the inclusion visit or planning to be exposed to artificial UV, excessive or prolonged natural sunlight during the study and up to 3 months after completion of study participation
* Subject hirsute on the target areas
* Subject having contraindication to the local anaesthetic used for biopsies
* Subject with known immune deficiency
* Subject with a recognised addiction to alcohol or drug
* Subject with a scar pathology or pathology with consequences for healing such as diabetes
* Subject with known history of hepatitis B or C or known HIV positive status
* Subject with hereditary or acquired haemostasis disorder
* Smoker \> 10 cigarettes/day with nicotine (or equivalent in electronic cigarettes)
* Criteria related to treatments and/or products:
* Surgical, chemical or significant invasive treatment on any of the target areas within 6 months before the inclusion or planned during the study
* Techniques with aesthetic aim on any of the target areas (laser, pulsed flash lamp etc.) or injections of reshaping products (collagen, hyaluronic acid, botulinic toxin etc.) within 6 months before the inclusion or planned during the study
* Oral isotretinoin taken within 6 months before the inclusion or planned during the study
* Phototherapy treatment on any of the target areas within 2 months before the inclusion or planned during the study
* Systemic treatment likely to affect haemostasis (anticoagulants, platelet antiaggregants, etc.) taken within the weeks before the inclusion or planned during the study
* Systemic treatment may interfere with the healing process (non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressants) taken within the weeks before the inclusion or planned during the study
* Systemic treatment or topical treatment applied on any target areas likely to interfere with the local anesthetic (anti-arhythmic, beta blockers etc.) within the weeks before the inclusion or planned during the study
* Topical non-steroidal anti-inflammatory, dermocorticoids, immunomodulators applied on any of the target areas within the 2 weeks before the inclusion or planned during the study
* Topical skincare product (e.g. exfoliation, scrub, body mask) applied on any of the target areas within 7 days before the inclusion or planned during the study
40 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SpinControl
UNKNOWN
Pierre Fabre Dermo Cosmetique
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elisabeth GUITTON-OUDET, Dr
Role: PRINCIPAL_INVESTIGATOR
SpinControl
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SpinControl
Tours, Indre et Loire, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RV4983A20240122
Identifier Type: -
Identifier Source: org_study_id